Back to top
more

Abbott Laboratories (ABT)

(Delayed Data from NYSE)

$127.29 USD

127.29
5,452,778

+1.10 (0.87%)

Updated Aug 1, 2025 03:59 PM ET

After-Market: $127.29 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value D Growth F Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 30% (173 out of 246)

Industry: Medical - Products

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Intersect ENT (XENT) SINUVA Implant Receives FDA Approval

by Zacks Equity Research

Intersect ENT's (XENT) consistent focus on the chronic sinusitis market is likely to lend the company a competitive edge in the niche space.

    Zacks Equity Research

    Global In Vitro Diagnostic Market Booms: Stocks in Focus

    by Zacks Equity Research

    With the emergence of complex and transmittable diseases worldwide, In Vitro Diagnostic within the MedTech space is currently in the spotlight.

      Zacks Equity Research

      DexCom-Lily Partnership to Boost CGM Platform, Customer Base

      by Zacks Equity Research

      DexCom (DXCM) continues to sign deals to boost CGM platform adoption.

        Zacks Equity Research

        HCA Healthcare (HCA) Posts In-Line Q3 Earnings, Keeps View

        by Zacks Equity Research

        HCA Healthcare's (HCA) third quarter witnesses increase in revenues and admissions. However, expenses too escalate. The company reiterates guidance provided earlier this month.

          Zacks Equity Research

          Abiomed (ABMD) Earnings and Revenues Beat Estimates in Q2

          by Zacks Equity Research

          Abiomed's (ABMD) strong performance in Impella heart pump boosted the company's second-quarter 2018 results.

            Zacks Equity Research

            Integra LifeSciences (IART) Misses on Q3 Earnings & Revenues

            by Zacks Equity Research

            Integra LifeSciences' (IART) raised full-year 2017 revenue guidance buoys optimism.

              Zacks Equity Research

              Align Technology (ALGN) Q3 Earnings Top on Invisalign Sales

              by Zacks Equity Research

              An extremely strong summer teen season drives Align Technology's (ALGN) Invisalign growth within the global teen market in the third quarter.

                Zacks Equity Research

                Chemed (CHE) Beats on Q3 Earnings & Revenues, View Revised

                by Zacks Equity Research

                Chemed (CHE) rides high on its Roto-Rooter business in Q3

                  Zacks Equity Research

                  ResMed (RMD) Q1 Earnings Top on Growth in All Business Lines

                  by Zacks Equity Research

                  ResMed (RMD) delivers a promising Q1 on the back of solid contributions from domestic and international businesses.

                    Zacks Equity Research

                    Stryker (SYK) Earnings and Revenues Beat Estimates in Q3

                    by Zacks Equity Research

                    Stryker (SYK) posted strong numbers in the third quarter owing to higher revenues.

                      Zacks Equity Research

                      Cerner (CERN) Misses on Q3 Earnings, Bookings Decline Y/Y

                      by Zacks Equity Research

                      Despite a tepid third quarter, Cerner's (CERN) bookings guidance for the fourth quarter is encouraging.

                        Zacks Equity Research

                        Varian Medical (VAR) Misses on Q4 Earnings, Issues FY18 View

                        by Zacks Equity Research

                        Year-over-year decline in Varian Medical's (VAR) proton therapy segment is the primary cause behind the company's lackluster fourth-quarter performance.

                          Zacks Equity Research

                          GNC Holdings (GNC) Lags Q3 Earnings & Revenues, Margins Down

                          by Zacks Equity Research

                          GNC Holdings (GNC) misses the Zacks Consensus Estimate on both the counts in Q3 due to adverse impact from the recent hurricanes and lower sales at the U.S. & Canada and manufacturing/wholesale segments.

                            Zacks Equity Research

                            Cardiovascular Systems (CSII) Q1 Earnings Top, Revenues Lag

                            by Zacks Equity Research

                            Cardiovascular Systems' (CSII) Q1 revenues declined year over year owing to the decline in revenues at both the segments.

                              Zacks Equity Research

                              Boston Scientific's (BSX) Q3 Earnings In Line, Guidance Up

                              by Zacks Equity Research

                              Despite back-to-back natural disasters, Boston Scientific managed to register strong year-over-year increase in both earnings and revenues in the third quarter on balanced growth across all segments.

                                Zacks Equity Research

                                McKesson (MCK) Beats Earnings & Revenue Estimates in Q2

                                by Zacks Equity Research

                                McKesson (MCK) reported strong second-quarter numbers owing to stable performance from Distribution Solutions business.

                                  Zacks Equity Research

                                  Zacks Industry Outlook Highlights: Johnson & Johnson, Abbott Labs, Medtronic and Boston Scientific.

                                  by Zacks Equity Research

                                  Zacks Industry Outlook Highlights: Johnson & Johnson, Abbott Labs, Medtronic and Boston Scientific.

                                    Zacks Equity Research

                                    Thermo Fisher (TMO) Q3 Earnings & Sales Top, Guidance Up

                                    by Zacks Equity Research

                                    On solid third-quarter performance, a favorable foreign exchange environment and the recently closed acquisition of Patheon, Thermo Fisher (TMO) has raised its full-year 2017 guidance.

                                      Zacks Equity Research

                                      LabCorp (LH) Beats Q3 Earnings Estimates, Raises Guidance

                                      by Zacks Equity Research

                                      Banking on strong third-quarter show and considering a gradually improving foreign exchange scenario, LabCorp (LH) increased its earlier provided 2017 outlook.

                                        Zacks Equity Research

                                        Walgreens Boots (WBA) Tops Q4 Earnings, Issues 2018 View

                                        by Zacks Equity Research

                                        Walgreens Boots (WBA) surpasses the Zacks Consensus Estimate for both the counts in Q4 on continued prescription growth and strength in the Retail Pharmacy USA division.

                                          Zacks Equity Research

                                          Baxter (BAX) Beats on Earnings & Sales in Q3, 2017 View Up

                                          by Zacks Equity Research

                                          Baxter (BAX) exited the third quarter on a solid note, courtesy of stellar performances by the company's hospital products and renal segments.

                                            Zacks Equity Research

                                            NuVasive (NUVA) Q3 Earnings Top, Revenues Lag, Guidance Cut

                                            by Zacks Equity Research

                                            NuVasive's robust top-line growth in Q3 was driven by strong international performance. However, U.S. sales declined on procedural volume challenges and an adverse impact of the recent natural disasters.

                                              Zacks Equity Research

                                              Accuray's (ARAY) Q1 Loss in Line, Revenues Beat Estimates

                                              by Zacks Equity Research

                                              Accuray (ARAY) rides high on its product and service segments in Q1.

                                                Zacks Equity Research

                                                Illumina (ILMN) Tops Q3 Earnings & Revenues, Raises Guidance

                                                by Zacks Equity Research

                                                Illumina (ILMN) rides high on sequencing consumables and instruments as well as microarray portfolios in Q3 earnings.

                                                  Zacks Equity Research

                                                  Abaxis (ABAX) Posts In-Line Earnings in Q2, Lags Revenues

                                                  by Zacks Equity Research

                                                  Abaxis (ABAX) misses the Zacks Consensus Estimate for revenues due to softness in the medical market in Q2. Weak margins are a concern as well.